Cell Therapy Market Research Report Information By Cell Type (Stem Cell, {Bone Marrow, Blood, Umbilical Cord-Derived, Adipose-Derived Stem Cell, and others [Placenta, and Nonspecific cells]}, and Non-stem Cell), By Therapy Type (Autologous, and Allogeneic), By Therapeutic Area (Malignancies, Musculoskeletal Disorders, Autoimmune Disorders, Dermatology, and others), By End-User (Hospitals & Clinics, and Academic & Research Institutes), and By Region (North America, Europe, Asia-Pacific, and the Rest of the World)—Forecast till 2030

ID: MRFR/LS/3630-CR | 95 Pages | Published By Kinjoll Dey on February 2021

1 Executive Summery

2 Market Introduction

2.1 Definition 15

2.2 Scope Of The Study 15

2.3 Assumptions & Limitations 15

2.3.1 Assumptions 15

2.3.2 Limitations 15

2.4 Market Structure 16

3 Research Methodology

3.1 Research Process 17

3.2 Primary Research 18

3.3 Secondary Research 19

3.4 Market Size Estimation 20

3.5 Forecast Model 20

4 Market Dynamics

4.1 Introduction 21

4.2 Drivers 22

4.2.1 Rise In Number Of Cell Therapy Clinical Studies 22

4.2.2 Rising Adoption Of Regenerative Medicine 22

4.3 Restraints 23

4.3.1 Ethical Concerns Related To Stem Cell Research 23

4.3.2 Stringent Regulatory Policies 23

4.4 Opportunities 23

4.4.1 Entering Developing Economies 23

5 Market Factor Analysis

5.1 Clinical Trial Data 24

5.2 Regulatory Guidelines 25

6 Cell Therapy Market, By Type

6.1 Overview 26

6.2 Autologous 27

6.3 Allogeneic 27

7 Cell Therapy Market, By Product

7.1 Overview 28

7.2 Consumables (Vessel/Media/Serum/Reagent) 30

7.3 Equipment 30

7.4 Software & Other Services 30

8 Cell Therapy Market, By Technique

8.1 Overview 31

8.2 Stem Cell Therapy 33

8.3 Cell Vaccine 33

8.4 Adoptive Cell Transfer (ACT) 34

8.5 Fibroblast Cell Therapy 34

8.6 Chondrocyte Cell Therapy 34

9 Cell Therapy Market, By Technology

9.1 Overview 35

9.2 Viral Vector Technology 37

9.3 Cell Immortalization Technology 37

9.4 Genome Editing Technology 37

10 Cell Therapy Market, By Cell Source

10.1 Overview 38

10.2 Bone Marrow 39

10.3 Adipose Tissue 40

10.4 Umbilical Cord Blood Derived Cells 40

11 Cell Therapy Market, By Application

11.1 Overview 41

11.2 Oncology 42

11.3 Cardiovascular Disease (CVD) 43

11.4 Orthopedic 43

11.5 Wound Healing 43

12 Cell Therapy Market, By End User

12.1 Overview 44

12.2 Hospital & Clinics 45

12.3 Regenerative Medicine Centers 46

12.4 Research Institutes 46

13 Global Cell Therapy Market, By Region

13.1 Overview 47

13.2 Americas 49

Cell Therapy Market, By Type

Cell Therapy Market, By Product

Cell Therapy Market, By Technique

Cell Therapy Market, By Technology

Cell Therapy Market, By Cell Source

Cell Therapy Market, By Application

Cell Therapy Market, By End User

13.2.1 North America 53

Cell Therapy Market, By Type

Cell Therapy Market, By Product

Cell Therapy Market, By Technique

Cell Therapy Market, By Technology

Cell Therapy Market, By Cell Source

Cell Therapy Market, By Application

Cell Therapy Market, By End User

13.2.2 South America 57

Cell Therapy Market, By Type

Cell Therapy Market, By Product

Cell Therapy Market, By Technique

Cell Therapy Market, By Technology

Cell Therapy Market, By Cell Source

Cell Therapy Market, By Application

Cell Therapy Market, By End User

13.3 Europe 61

Cell Therapy Market, By Type

Cell Therapy Market, By Product

Cell Therapy Market, By Technique

Cell Therapy Market, By Technology

Cell Therapy Market, By Cell Source

Cell Therapy Market, By Application

Cell Therapy Market, By End User

13.4 Asia-Pacific 65

Cell Therapy Market, By Type

Cell Therapy Market, By Product

Cell Therapy Market, By Technique

Cell Therapy Market, By Technology

Cell Therapy Market, By Cell Source

Cell Therapy Market, By Application

Cell Therapy Market, By End User

13.5 Middle East & Africa 69

Cell Therapy Market, By Type

Cell Therapy Market, By Product

Cell Therapy Market, By Technique

Cell Therapy Market, By Technology

Cell Therapy Market, By Cell Source

Cell Therapy Market, By Application

Cell Therapy Market, By End User

14 Competitive Landscape

14.1 Introduction 73

15 Company Profiles

15.1 Mesoblast Ltd 74

15.1.1 Company Overview 74

15.1.2 Financial Overview 74

15.1.3 Products/Services Offered 74

15.1.4 Key Developments 75

15.1.5 SWOT Analysis 75

15.1.6 Key Strategies 75

15.2 Vericel Corporation 76

15.2.1 Company Overview 76

15.2.2 Financial Overview 76

15.2.3 Products/Services Offered 76

15.2.4 Key Developments 77

15.2.5 SWOT Analysis 77

15.2.6 Key Strategies 77

15.3 Osiris Therapeutics, Inc. 78

15.3.1 Company Overview 78

15.3.2 Financial Overview 78

15.3.3 Products/Services Offered 78

15.3.4 Key Developments 79

15.3.5 SWOT Analysis 79

15.3.6 Key Strategies 79

15.4 JCR Pharmaceuticals Co., Ltd 80

15.4.1 Company Overview 80

15.4.2 Financial Overview 80

15.4.3 Products/Services Offered 81

15.4.4 Key Developments 81

15.4.5 SWOT Analysis 81

15.4.6 Key Strategies 82

15.5 NuVasive, Inc. 83

15.5.1 Company Overview 83

15.5.2 Financial Overview 83

15.5.3 Products/Services Offered 84

15.5.4 Key Developments 84

15.5.5 SWOT Analysis 84

15.5.6 Key Strategies 85

15.6 Pharmicell Co., Ltd 86

15.6.1 Company Overview 86

15.6.2 Financial Overview 86

15.6.3 Products/Services Offered 86

15.6.4 Key Developments 86

15.6.5 SWOT Analysis 86

15.6.6 Key Strategies 86

15.7 RTI Surgical Holdings, Inc. 87

15.7.1 Company Overview 87

15.7.2 Financial Overview 87

15.7.3 Products/Services Offered 88

15.7.4 Key Developments 88

15.7.5 SWOT Analysis 89

15.7.6 Key Strategies 89

15.8 AlloSource 90

15.8.1 Company Overview 90

15.8.2 Financial Overview 90

15.8.3 Products/Services Offered 90

15.8.4 Key Developments 91

15.8.5 SWOT Analysis 91

15.8.6 Key Strategies 91

15.9 Holostem Terapie Avanzate S.R.L. 92

15.9.1 Company Overview 92

15.9.2 Financial Overview 92

15.9.3 Products/Services Offered 92

15.9.4 Key Developments 92

15.9.5 SWOT Analysis 92

15.9.6 Key Strategies 92

15.10 Medipost Co., Ltd 93

15.10.1 Company Overview 93

15.10.2 Financial Overview 93

15.10.3 Products/Services Offered 94

15.10.4 Key Developments 94

15.10.5 SWOT Analysis 94

15.10.6 Key Strategies 94

16 Appendix

16.1 References 95

16.2 Related Reports 95

17 List Of Tables

TABLE 1 PRIMARY INTERVIEWS 18

TABLE 2 CELL THERAPY CLINICAL TRIALS IN 2018, BY PHASE 24

TABLE 3 CELL THERAPY CLINICAL TRIALS, BY TYPE (2018) 24

TABLE 4 GLOBAL CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 26

TABLE 5 GLOBAL CELL THERAPY MARKET, FOR AUTOLOGOUS, BY REGION, 2020–2027 (USD MILLION) 27

TABLE 6 GLOBAL CELL THERAPY MARKET, FOR ALLOGENEIC, BY REGION, 2020–2027 (USD MILLION) 27

TABLE 7 GLOBAL CELL THERAPY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 28

TABLE 8 GLOBAL CELL THERAPY MARKET, FOR CONSUMABLES (VESSEL/MEDIA/SERUM/REAGENT), BY REGION, 2020–2027 (USD MILLION) 30

TABLE 9 GLOBAL CELL THERAPY MARKET, FOR EQUIPMENT, BY REGION, 2020–2027 (USD MILLION) 30

TABLE 10 GLOBAL CELL THERAPY MARKET, FOR SOFTWARE & OTHER SERVICES, BY REGION, 2020–2027 (USD MILLION) 30

TABLE 11 GLOBAL CELL THERAPY MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 32

TABLE 12 GLOBAL CELL THERAPY MARKET, FOR STEM CELL THERAPY, BY REGION, 2020–2027 (USD MILLION) 33

TABLE 13 GLOBAL CELL THERAPY MARKET, FOR CELL VACCINE, BY REGION, 2020–2027 (USD MILLION) 33

TABLE 14 GLOBAL CELL THERAPY MARKET, FOR ADOPTIVE CELL TRANSFER (ACT), BY REGION, 2020–2027 (USD MILLION) 34

TABLE 15 GLOBAL CELL THERAPY MARKET, FOR FIBROBLAST CELL THERAPY, BY REGION, 2020–2027 (USD MILLION) 34

TABLE 16 GLOBAL CELL THERAPY MARKET, FOR CHONDROCYTE CELL THERAPY, BY REGION, 2020–2027 (USD MILLION) 34

TABLE 17 GLOBAL CELL THERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 36

TABLE 18 GLOBAL CELL THERAPY MARKET, FOR VIRAL VECTOR TECHNOLOGY, BY REGION, 2020–2027 (USD MILLION) 37

TABLE 19 GLOBAL CELL THERAPY MARKET, FOR CELL IMMORTALIZATION TECHNOLOGY, BY REGION, 2020–2027 (USD MILLION) 37

TABLE 20 GLOBAL CELL THERAPY MARKET, FOR GENOME EDITING TECHNOLOGY, BY REGION, 2020–2027 (USD MILLION) 37

TABLE 21 GLOBAL CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION) 38

TABLE 22 GLOBAL CELL THERAPY MARKET, FOR BONE MARROW, BY REGION, 2020–2027 (USD MILLION) 39

TABLE 23 GLOBAL CELL THERAPY MARKET, FOR ADIPOSE TISSUE, BY REGION, 2020–2027 (USD MILLION) 40

TABLE 24 GLOBAL CELL THERAPY MARKET, FOR UMBILICAL CORD BLOOD DERIVED CELLS, BY REGION, 2020–2027 (USD MILLION) 40

TABLE 25 GLOBAL CELL THERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 41

TABLE 26 GLOBAL CELL THERAPY MARKET, FOR ONCOLOGY, BY REGION, 2020–2027 (USD MILLION) 42

TABLE 27 GLOBAL CELL THERAPY MARKET, FOR CARDIOVASCULAR DISEASE (CVD), BY REGION, 2020–2027 (USD MILLION) 43

TABLE 28 GLOBAL CELL THERAPY MARKET, FOR ORTHOPEDIC, BY REGION, 2020–2027 (USD MILLION) 43

TABLE 29 GLOBAL CELL THERAPY MARKET, FOR WOUND HEALING, BY REGION, 2020–2027 (USD MILLION) 43

TABLE 30 GLOBAL CELL THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 44

TABLE 31 GLOBAL CELL THERAPY MARKET, FOR HOSPITAL & CLINICS, BY REGION, 2020–2027 (USD MILLION) 45

TABLE 32 GLOBAL CELL THERAPY MARKET, FOR REGENERATIVE MEDICINE CENTERS, BY REGION, 2020–2027 (USD MILLION) 46

TABLE 33 GLOBAL CELL THERAPY MARKET, FOR RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION) 46

TABLE 34 GLOBAL CELL THERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 47

TABLE 35 AMERICAS: CELL THERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 49

TABLE 36 AMERICAS: CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 50

TABLE 37 AMERICAS: CELL THERAPY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 50

TABLE 38 AMERICAS: CELL THERAPY MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 50

TABLE 39 AMERICAS: CELL THERAPY MARKET, FOR STEM CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 51

TABLE 40 AMERICAS: CELL THERAPY MARKET, FOR CELL VACCINE, BY TYPE, 2020–2027 (USD MILLION) 51

TABLE 41 AMERICAS: CELL THERAPY MARKET, FOR ADOPTIVE CELL TRANSFER (ACT), BY TYPE, 2020–2027 (USD MILLION) 51

TABLE 42 AMERICAS: CELL THERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 52

TABLE 43 AMERICAS: CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION) 52

TABLE 44 AMERICAS: CELL THERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 52

TABLE 45 AMERICAS: CELL THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 53

TABLE 46 NORTH AMERICA: CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 53

TABLE 47 NORTH AMERICA: CELL THERAPY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 53

TABLE 48 NORTH AMERICA: CELL THERAPY MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 54

TABLE 49 NORTH AMERICA: CELL THERAPY MARKET, FOR STEM CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 54

TABLE 50 NORTH AMERICA: CELL THERAPY MARKET, FOR CELL VACCINE, BY TYPE, 2020–2027 (USD MILLION) 54

TABLE 51 NORTH AMERICA: CELL THERAPY MARKET, FOR ADOPTIVE CELL TRANSFER (ACT), BY TYPE, 2020–2027 (USD MILLION) 55

TABLE 52 NORTH AMERICA: CELL THERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 55

TABLE 53 NORTH AMERICA: CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION) 55

TABLE 54 NORTH AMERICA: CELL THERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 56

TABLE 55 NORTH AMERICA: CELL THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 56

TABLE 56 SOUTH AMERICA: CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 57

TABLE 57 SOUTH AMERICA: CELL THERAPY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 57

TABLE 58 SOUTH AMERICA: CELL THERAPY MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 57

TABLE 59 SOUTH AMERICA: CELL THERAPY MARKET, FOR STEM CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 58

TABLE 60 SOUTH AMERICA: CELL THERAPY MARKET, FOR CELL VACCINE, BY TYPE, 2020–2027 (USD MILLION) 58

TABLE 61 SOUTH AMERICA: CELL THERAPY MARKET, FOR ADOPTIVE CELL TRANSFER (ACT), BY TYPE, 2020–2027 (USD MILLION) 58

TABLE 62 SOUTH AMERICA: CELL THERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 59

TABLE 63 SOUTH AMERICA: CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION) 59

TABLE 64 SOUTH AMERICA: CELL THERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 59

TABLE 65 SOUTH AMERICA: CELL THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 60

TABLE 66 EUROPE: CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 61

TABLE 67 EUROPE: CELL THERAPY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 61

TABLE 68 EUROPE: CELL THERAPY MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 62

TABLE 69 EUROPE: CELL THERAPY MARKET, FOR STEM CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 62

TABLE 70 EUROPE: CELL THERAPY MARKET, FOR CELL VACCINE, BY TYPE, 2020–2027 (USD MILLION) 62

TABLE 71 EUROPE: CELL THERAPY MARKET, FOR ADOPTIVE CELL TRANSFER (ACT), BY TYPE, 2020–2027 (USD MILLION) 63

TABLE 72 EUROPE: CELL THERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 63

TABLE 73 EUROPE: CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION) 63

TABLE 74 EUROPE: CELL THERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 64

TABLE 75 EUROPE: CELL THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 64

TABLE 76 ASIA-PACIFIC: CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 65

TABLE 77 ASIA-PACIFIC: CELL THERAPY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 65

TABLE 78 ASIA-PACIFIC: CELL THERAPY MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 66

TABLE 79 ASIA-PACIFIC: CELL THERAPY MARKET, FOR STEM CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 66

TABLE 80 ASIA-PACIFIC: CELL THERAPY MARKET, FOR CELL VACCINE, BY TYPE, 2020–2027 (USD MILLION) 66

TABLE 81 ASIA-PACIFIC: CELL THERAPY MARKET, FOR ADOPTIVE CELL TRANSFER (ACT), BY TYPE, 2020–2027 (USD MILLION) 67

TABLE 82 ASIA-PACIFIC: CELL THERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 67

TABLE 83 ASIA-PACIFIC: CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION) 67

TABLE 84 ASIA-PACIFIC: CELL THERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 68

TABLE 85 ASIA-PACIFIC: CELL THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 68

TABLE 86 MIDDLE EAST & AFRICA: CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 69

TABLE 87 MIDDLE EAST & AFRICA: CELL THERAPY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 69

TABLE 88 MIDDLE EAST & AFRICA: CELL THERAPY MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 70

TABLE 89 MIDDLE EAST & AFRICA: CELL THERAPY MARKET, FOR STEM CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 70

TABLE 90 MIDDLE EAST & AFRICA: CELL THERAPY MARKET, FOR CELL VACCINE, BY TYPE, 2020–2027 (USD MILLION) 70

TABLE 91 MIDDLE EAST & AFRICA: CELL THERAPY MARKET, FOR ADOPTIVE CELL TRANSFER (ACT), BY TYPE, 2020–2027 (USD MILLION) 71

TABLE 92 MIDDLE EAST & AFRICA: CELL THERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 71

TABLE 93 MIDDLE EAST & AFRICA: CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION) 71

TABLE 94 MIDDLE EAST & AFRICA: CELL THERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 72

TABLE 95 MIDDLE EAST & AFRICA: CELL THERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 72

TABLE 96 TOP MANUFACTURERS IN THE GLOBAL CELL THERAPY MARKET 73

18 List Of Figures

FIGURE 1 MARKET SYNOPSIS 14

FIGURE 2 GLOBAL CELL THERAPY MARKET: MARKET STRUCTURE 16

FIGURE 3 RESEARCH PROCESS 17

FIGURE 4 TOP-DOWN & BOTTOM-UP APPROACH 20

FIGURE 5 GLOBAL CELL THERAPY MARKET SHARE, BY TYPE, 2020 (%) 26

FIGURE 6 GLOBAL CELL THERAPY MARKET, BY TYPE, 2020 & 2027 (USD MILLION) 27

FIGURE 7 GLOBAL CELL THERAPY MARKET SHARE, BY PRODUCT, 2020 (%) 29

FIGURE 8 GLOBAL CELL THERAPY MARKET, BY PRODUCT, 2020 & 2027 (USD MILLION) 29

FIGURE 9 GLOBAL CELL THERAPY MARKET SHARE, BY TECHNIQUE, 2020 (%) 32

FIGURE 10 GLOBAL CELL THERAPY MARKET, BY TECHNIQUE, 2020 & 2027 (USD MILLION) 33

FIGURE 11 GLOBAL CELL THERAPY MARKET SHARE, BY TECHNOLOGY, 2020 (%) 36

FIGURE 12 GLOBAL CELL THERAPY MARKET, BY TECHNOLOGY, 2020 & 2027 (USD MILLION) 36

FIGURE 13 GLOBAL CELL THERAPY MARKET SHARE, BY CELL SOURCE, 2020 (%) 39

FIGURE 14 GLOBAL CELL THERAPY MARKET, BY CELL SOURCE, 2020 & 2027 (USD MILLION) 39

FIGURE 15 GLOBAL CELL THERAPY MARKET SHARE, BY APPLICATION, 2020 (%) 42

FIGURE 16 GLOBAL CELL THERAPY MARKET, BY APPLICATION, 2020 & 2027 (USD MILLION) 42